Small molecule · developed by Bellus Health Inc. - a GSK company
BLU-5937 IR is an immediate-release oral formulation of BLU-5937, studied in a clinical trial in healthy subjects and in cough.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05570539 | Phase 1 | Cough | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CoughHealthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →